Journal
AMERICAN JOURNAL OF THERAPEUTICS
Volume 17, Issue 2, Pages 176-181Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MJT.0b013e3181c6c0b2
Keywords
androgen receptor; castration-resistant prostate cancer; MDV3100; abiraterone
Categories
Funding
- NATIONAL CANCER INSTITUTE [ZIASC010098, ZIABC010547] Funding Source: NIH RePORTER
- Intramural NIH HHS [Z01 BC010547-05] Funding Source: Medline
Ask authors/readers for more resources
Androgens play a critical role in the progression of castration-resistant prostate cancer through androgen receptor (AR)-regulated signaling pathways. Progress has been made in the development of potent agents designed to suppress androgen function by blocking the AR, inhibiting the synthesis of androgens, or targeting downstream AR signaling pathways. This review summarizes the development of novel therapies based on current insights into AR signaling pathways in castration-resistant prostate cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available